Session v. 4D Molecular Therapeutics, Inc.

District Court, N.D. California·Decided December 2, 2020·No. 3:20-cv-05407·Unknown

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 NORTHERN DISTRICT OF CALIFORNIA 10 San Francisco Division 11 R.A. SESSION, II Case No. 20-cv-05407-LB

12 Plaintiff, ORDER GRANTING MOTION TO 13 v. DISMISS COUNTERCLAIMS

14 4D MOLECULAR THERAPEUTICS INC, Re: ECF No. 17 15 Defendant. 16 17 INTRODUCTION 18 The plaintiff, R.A. Session, worked for the defendant, 4D Molecular Therapeutics Inc., as a 19 chief business officer and (later) as a consultant, and he sued 4D for allegedly not honoring stock 20 options promised in a separation contract that memorialized a consulting arrangement. He claimed 21 breach of contract and fraud and asked for declaratory relief.1 4D countersued for breach of the 22 parties’ underlying employment contract, which preceded the separation agreement and prohibited 23 certain outside activities. 4D also alleged fraud.2 Mr. Session moved to dismiss the counterclaims 24 under Federal Rule of Procedure 12(b)(6) on the grounds that (1) the separation contract 25 26 27 1 Compl. – ECF No. 2. Citations refer to material in the Electronic Case File (“ECF”); pinpoint citations are to the ECF-generated page numbers at the top of documents. 1 superseded the earlier employment contract and the economic-loss rule prohibits the fraud claims, 2 and (2) 4D did not plead fraud with particularity under Rule 9(b). The court grants the motion. 3 4 STATEMENT 5 In June 2018, 4D — a company that develops gene therapies to address genetic diseases — 6 hired Mr. Session (based in Dallas, Texas) to be its chief business officer and head of corporate 7 strategy, with (pursuant to an employment agreement) a base salary of $334,800, a discretionary 8 40-percent bonus, a bonus of $200,000 for closing a qualified financing, and stock options.3 As to 9 the stock options, under the employment agreement and another grant to Mr. Session, Mr. Session 10 had the option to buy 286,516 shares of 4D common stock (about two to three percent of the 11 company).4 For reasons involving Mr. Session’s outside activities, the parties ended their 12 employment relationship and — on February 12, 2019 — replaced the employment agreement 13 with a consulting agreement retaining Mr. Session as a strategy advisor with compensation in the 14 form of a monthly payment of $10,000 and 140,000 in stock options vesting over four years 15 (subject to the approval of the options grant by 4D’s board of directors). The agreement also 16 defined what happened if 4D terminated the consulting agreement. For example, 35,000 shares 17 would vest if 4D terminated the agreement before August 1, 2019, and, if 4D terminated the 18 agreement within the first year, Mr. Session would receive a final payment of $30,000.5 In 19 September 2019, allegedly because of 4D’s contemplated initial public offering and not because of 20 any employment issues, 4D ended the consulting agreement.6 4D also informed Mr. Session that 21 its board of directors never approved 140,000 in options and approved only 35,000 in options, 22 23

24 3 Compl. – ECF No. 2 at 3 (¶ 9); Counterclaims – ECF No. 9 at 11 (¶ 85); Offer Letter, Ex. A to 25 Counterclaims – ECF No. 9-1 at 1–2. The court considers the parties’ contracts (attached to the complaint and submitted in support of the motion to dismiss). Knievel v. ESPN, 393 F.3d 1068, 1076 26 (9th Cir. 2005). 4 Compl. – ECF No. 2 at 3 (¶ 9). 27 5 Id. at 5 (¶ 16); Consultant Agreement, Ex. C to Counterclaims – ECF No. 9-3 at 2 (§ 4(c)), 7. 1 resulting in (according to 4D) an entitlement to about 5,000 options under the vesting schedule.7 2 Mr. Session then sued to recover the full stock options. 3 4D countersued for breach of the underlying employment contract, generally on the ground 4 that Mr. Session could not engage in outside employment or business activities related to 4D’s 5 business, but he did so by working as an advisor for other companies. 4D also claims fraud.8 6 The parties are diverse, and the amount in controversy exceeds $75,000.9 28 U.S.C. § 1332. 7 Mr. Session moved to dismiss the counterclaims.10 The parties consented to the court’s 8 jurisdiction.11 The court held a hearing on December 1, 2020. 9 . 10 STANDARD OF REVIEW 11 A complaint must contain a “short and plain statement of the claim showing that the pleader is 12 entitled to relief” to give the defendant “fair notice” of what the claims are and the grounds upon 13 which they rest. Fed. R. Civ. P. 8(a)(2); Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007). A 14 complaint does not need detailed factual allegations, but “a plaintiff’s obligation to provide the 15 ‘grounds’ of his ‘entitlement to relief’ requires more than labels and conclusions, and a formulaic 16 recitation of the elements of a cause of action will not do. Factual allegations must be enough to 17 raise a claim for relief above the speculative level[.]” Twombly, 550 U.S. at 555 (cleaned up). 18 To survive a motion to dismiss, a complaint must contain sufficient factual allegations, which 19 when accepted as true, “‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 20 U.S. 662, 678 (2009) (quoting Twombly, 550 U.S. at 570). “A claim has facial plausibility when 21 the plaintiff pleads factual content that allows the court to draw the reasonable inference that the 22 defendant is liable for the misconduct alleged.” Id. “The plausibility standard is not akin to a 23 24 7 Id. at 7–8 (¶¶ 23–24). 25 8 Employment Agreement, Ex. B to Counterclaims – ECF No. 9-2 at 5; Counterclaims – ECF No. 9 at 26 12 (¶ 89), 14–17 (¶¶ 99–125). 9 Notice of Removal – ECF No. 1 at 2–4 (¶¶ 4–10). 27 10 Mot. – ECF No. 17. 1 ‘probability requirement,’ but it asks for more than a sheer possibility that a defendant has acted 2 unlawfully.” Id. (citing Twombly, 550 U.S. at 557). “Where a complaint pleads facts that are 3 merely consistent with a defendant’s liability, it stops short of the line between possibility and 4 plausibility of ‘entitlement to relief.’” Id. (cleaned up) (quoting Twombly, 550 U.S. at 557). 5 Fraud allegations elicit a more demanding standard. Rule 9(b) provides: “In alleging fraud . . ., 6 a party must state with particularity the circumstances constituting fraud. . . . Malice, intent, 7 knowledge, and other conditions of a person’s mind may be alleged generally.” Fed. R. Civ. P. 8 9(b). This means that “[a]verments of fraud must be accompanied by the ‘who, what, when, 9 where, and how’ of the misconduct charged.” Vess v. Ciba–Geigy Corp. USA, 317 F.3d 1097, 1106 10 (9th Cir. 2003). Like the basic “notice pleading” demands of Rule 8, a driving concern of Rule 11 9(b) is that defendants be given fair notice of the charges against them. See, e.g., In re Lui, 646 F. 12 App’x 571, 573 (9th Cir. 2016) (“Rule 9(b) demands that allegations of fraud be specific enough 13 to give defendants notice of the particular misconduct . . . so that they can defend against the 14 charge and not just deny that they have done anything wrong.”) (quotation omitted); Odom v. 15 Microsoft Corp., 486 F.3d 541, 553 (9th Cir. 2007) (Rule 9(b) requires particularity “so that the 16 defendant can prepare an adequate answer”).

Free access — add to your briefcase to read the full text and ask questions with AI

Session v. 4D Molecular Therapeutics, Inc., (N.D. Cal. 2020).

Session v. 4D Molecular Therapeutics, Inc. (Session v. 4D Molecular Therapeutics, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Oakland Raiders v. Oakland-Alameda County Coliseum, Inc.
51 Cal. Rptr. 3d 144 (California Court of Appeal, 2006)
Wise v. Pena
552 S.W.2d 196 (Court of Appeals of Texas, 1977)
Robinson Helicopter Co., Inc. v. Dana Corp.
102 P.3d 268 (California Supreme Court, 2004)
Vess v. Ciba-Geigy Corp. USA
317 F.3d 1097 (Ninth Circuit, 2003)
United States v. United Healthcare Insurance Co.
848 F.3d 1161 (Ninth Circuit, 2016)